FIP Veterinary Advisor

2. Preponderance of Evidence Approach

FIP diagnosis requires multiple supporting findings - never one test alone:

• Weight signalment, history, clinical signs, and laboratory findings together
• Use diagnostic flowcharts systematically
• Consider overall clinical picture over isolated test abnormalities

3. Treatment is Now Possible

GS-441524 has transformed FIP from uniformly fatal to >85% curable:

• Provide realistic hope while maintaining honesty about challenges
• Support veterinarians working with clients using various drug sources
• Focus on patient welfare regardless of drug procurement method

Quick Reference Guide

Diagnosis Checklist

High Suspicion Indicators:

• Age <2 years with multi-cat household
• Persistent fever non-responsive to antibiotics
• Swollen abdomen (effusion) or dyspnoea
• Hyperglobulinaemia with low A:G ratio (<0.4)
• Effusion: High protein (>35 g/L), low cells (<5×10⁹/L), yellow, Rivalta positive
• Ocular changes (iris color change, uveitis, perivascular cuffing)
• Progressive neurological signs

Proceed to Diagnostic Flowcharts: See diagnostic-flowcharts.md for detailed decision trees.

Treatment Quick Start

Initial Dosing (GS-441524):

• Wet/dry FIP (no CNS/ocular): 4-6 mg/kg SC daily × 12 weeks
• Ocular FIP: 8 mg/kg SC daily × 12 weeks
• Neurological FIP: 10 mg/kg SC daily × 12 weeks

Essential Monitoring:

• Weekly: Weight, temperature, clinical signs
• Monthly: CBC and chemistry panel (focus on hematocrit, globulin, albumin, A:G ratio)

For detailed protocols: See treatment-protocols.md

Workflow: Diagnostic Approach

Step 1: Initial Assessment

Gather complete information:

Signalment & History:

• Age, breed, sex
• Multi-cat household?
• Recent stressors (rehoming, vaccination, neutering)?
• Siblings or contacts with FIP?
• Duration and progression of clinical signs

Physical Examination:

• Temperature, weight, body condition score
• Presence of effusion (abdominal, thoracic, pericardial)
• Ocular examination (uveitis, iris changes, retinal changes)
• Neurological assessment (ataxia, paresis, seizures)
• Abdominal palpation (organomegaly, masses, lymph nodes)

Laboratory Tests:

• CBC: Look for anemia, lymphopenia, microcytosis
• Chemistry: Total protein, albumin, globulin, A:G ratio, bilirubin
• Alpha-1-acid glycoprotein if available

Step 2: Categorize Clinical Presentation

Determine which diagnostic tree to follow:

Tree A - Effusion Present: Use when fluid detected by POCUS or physical exam → See diagnostic-flowcharts.md - Tree A

Tree B - No Effusion, Non-specific Signs: Use when no fluid but suspicious clinical picture → See diagnostic-flowcharts.md - Tree B

Tree C - Neurological Signs: Use when neurological abnormalities predominate → See diagnostic-flowcharts.md - Tree C

Tree D - Ocular Signs: Use when ocular abnormalities predominate → See diagnostic-flowcharts.md - Tree D

Step 3: Perform Confirmatory Testing

Based on diagnostic tree:

Effusion Analysis:

• Biochemistry: Protein, Rivalta test, A:G ratio
• Cytology: Cell count, cell types
• FCoV RT-PCR (quantitative preferred - high loads more specific)
• Immunostaining for FCoV antigen (high specificity)

Tissue Sampling (FNA or Biopsy):

• Target abnormal organs (lymph nodes, kidney, liver, spleen)
• Cytology assessment
• FCoV RT-PCR
• Immunostaining for FCoV antigen

Gold Standard:

• Histopathology consistent with FIP
• Positive immunohistochemistry for FCoV antigen in lesions

Step 4: Rule Out Differential Diagnoses

Consider and systematically exclude other conditions:

Key Differentials by Presentation:

For effusive disease:

• Lymphocytic cholangitis, pyothorax, septic peritonitis, congestive heart failure, lymphoma

For neurological disease:

• Toxoplasmosis, trauma, thiamine deficiency, middle ear disease

For ocular disease:

• Toxoplasmosis, lymphoma, bartonellosis

Full differential diagnosis guidance: See differential-diagnosis.md

Step 5: Establish Diagnosis Confidence Level

Confirmed FIP:

• Histopathology + positive immunohistochemistry

FIP Very Likely:

• Positive immunostaining on effusion/FNA/CSF with consistent clinical picture
• High FCoV RNA loads on RT-PCR with consistent cytology and clinical signs

FIP Possible:

• Clinical signs + laboratory findings suggestive, but confirmatory tests not yet performed or inconclusive

FIP Less Likely:

• Negative confirmatory tests
• Alternative diagnosis more consistent with findings

Workflow: Treatment Planning

Phase 1: Pre-treatment Assessment

Confirm Diagnosis:

• Establish diagnosis confidence level
• Collect samples for FCoV detection if not already done
• Document baseline parameters

Baseline Documentation:

• Complete CBC and chemistry panel
• Body weight
• Temperature
• Photographs of clinical signs (effusion, ocular lesions)
• Activity level and appetite assessment

Client Communication:

• Explain diagnosis and prognosis
• Discuss treatment options (including legal status, costs, duration)
• Set realistic expectations (>85% cure rate with proper protocol)
• Discuss monitoring requirements
• Obtain informed consent

Phase 2: Initial Treatment

Select Starting Dose:

Determine appropriate dosage based on disease form:

• Wet/dry FIP without CNS or ocular involvement: 4-6 mg/kg daily SC
• FIP with ocular involvement: 8 mg/kg daily SC
• FIP with neurological involvement: 10 mg/kg daily SC

Administration Guidance:

• Injectable GS-441524 preferred (oral acceptable if ≤10 mg/kg equivalent)
• Subcutaneous injection
• Rotate injection sites systematically
• Consider gabapentin pre-treatment (5-10 mg/kg PO) for injection pain

Supportive Care:

• Nutritional support (appetite stimulants if needed)
• Fluid therapy if dehydrated
• Thoracocentesis only if dyspnoeic
• Analgesics as needed
• Short-term prednisolone acceptable for severe inappetence (few days only)

For comprehensive treatment protocols: See treatment-protocols.md

Phase 3: Monitoring Protocol

Daily/Weekly Owner Monitoring:

• Daily temperature
• Weekly weight
• Activity level and appetite
• Clinical signs progression or resolution

Veterinary Monitoring:

• Blood work every 4 weeks (minimum)
• CBC: Hematocrit, lymphocyte count
• Chemistry: Total protein, albumin, globulin, A:G ratio, bilirubin

Expected Response Timeline:

• 24-72 hours: Temperature normalization, appetite improvement
• 2-4 weeks: Near-normal behavior, effusion resolution, weight gain starting
• 8-10 weeks: Blood values normalizing, activity surge
• 12 weeks: Treatment completion assessment

Response Assessment: Create graphs tracking weight, temperature, A:G ratio, globulin over time for objective monitoring.

Phase 4: Dosage Adjustments

Weekly Weight Adjustments:

• Adjust dose for weight gain weekly
• Do not decrease dose for initial weight loss
• Significant weight gain expected (some cats double body weight)

Increase Dosage If:

• Slow improvement in clinical signs
• Blood values not improving adequately (after 4-8 weeks)
• Poor activity levels despite treatment
• Original clinical signs not resolving
• Development of ocular signs during treatment (increase to 8 mg/kg)
• Development of neurological signs during treatment (increase to 10 mg/kg)

How to Increase:

• Add 2-5 mg/kg to daily dose
• Continue increased dose minimum 4 weeks
• Extend total treatment duration to accommodate
• Expect positive response within days to 2 weeks

No Response to Increase:

• Consider further increase if <15 mg/kg
• Evaluate drug quality
• Reassess diagnosis
• Consider drug resistance developing
• Evaluate for concurrent disease

Phase 5: Treatment Completion

Assess All Criteria Before Stopping:

Outward Health Signs (all required):

• Normal activity level
• Normal appetite
• Appropriate weight gain/growth
• Quality coat (excellent indicator)
• Clinical signs resolved

Blood Test Normalization (all required):

• Hematocrit normal
• Lymphocyte count normal
• Total protein normal
• Albumin normal
• Globulin normal or near-normal
• A:G ratio normalized

Additional Considerations:

• Minimum 12 weeks treatment completed
• No fever
• No effusion
• No neurological or ocular signs

Critical Principle: Focus on OVERALL clinical picture. Do not extend treatment based solely on single marginally abnormal value if cat is otherwise healthy and all other parameters normal.

Phase 6: Post-Treatment Monitoring

12-Week Observation Period:

• Continue monitoring weight, activity, appetite
• Blood work at 4 and 8 weeks post-treatment
• Watch for relapse signs

Relapse Indicators:

• Return of fever
• New neurological signs
• New ocular signs
• Weight loss
• Decreased activity
• Rising globulin or falling A:G ratio

Relapse Management: If relapse occurs:

• Restart treatment at higher dose (minimum previous dose + 5 mg/kg)
• Duration: Minimum 8 weeks
• Use injectable form only (especially if >10 mg/kg)
• See treatment-protocols.md - Relapse Management

Workflow: Prevention and Multi-Cat Management

When clients have multiple cats or are concerned about prevention after an FIP diagnosis:

Risk Assessment

Evaluate environment:

• Number of cats in household
• Group stability (additions/removals)
• Hygiene practices
• Stress levels
• Space availability

Provide guidance based on risk level:

• Low risk (1-3 stable cats): Basic hygiene, monitor for illness
• Moderate risk (4-6 cats): Enhanced hygiene, stress reduction
• High risk (>6 cats, cattery, shelter): Rigorous protocols, consider testing

Full prevention guidance: See prevention-management.md

After FIP Diagnosis in Multi-Cat Household

Immediate advice:

• Other cats likely already exposed to FCoV (not mutated form)
• No need to isolate FIP cat from stable household
• Focus on stress reduction for all cats
• Monitor others for clinical signs (siblings highest risk)

Long-term recommendations:

• No routine testing of other cats needed
• Excellent litter box hygiene
• Avoid adding new cats during treatment period
• Watch for FIP signs in young cats/siblings

Cattery or Breeding Questions

When FIP occurs:

• Pause breeding temporarily
• Consider testing breeding cats for FCoV shedding
• Siblings of FIP cat at higher risk
• Do NOT cull entire cattery
• Do NOT use antivirals prophylactically

Prevention strategies:

• Small stable groups
• Early weaning and kitten separation
• Minimize stress
• Maintain genetic diversity
• See full cattery guidance in prevention-management.md

Workflow: Managing Complex Cases

Drug Resistance

Recognition:

• Inadequate response despite dosage increases
• Disease progression on treatment
• Relapse shortly after treatment completion

Management:

• Escalate dosage up to 15 mg/kg
• Consider combination therapy (GC376 + GS-441524) if available
• May achieve disease control without cure
• Quality of life assessment if resistance progresses

Full guidance: See treatment-protocols.md - Drug Resistance

Neurological FIP

Special Considerations:

• Higher starting dose required (10 mg/kg minimum)
• Blood-brain barrier limits drug penetration
• Higher relapse risk
• Permanent CNS damage possible even with cure

Monitoring:

• Standard protocols plus neurological assessment
• Advanced imaging (MRI) may be needed
• CSF analysis for diagnosis and monitoring

Prognosis:

• Lower cure rate than wet/dry FIP
• Some permanent deficits may persist even after virus clearance
• Peripheral nerve damage may slowly recover
• Central nervous system damage typically permanent

Injection Site Reactions

Prevention:

• Systematic site rotation
• Proper injection technique (subcutaneous, not intramuscular)
• Avoid between-shoulder area

Management:

• Gabapentin pre-medication
• Clean 4+ times daily with dilute hydrogen peroxide (1:5)
• Usually heal within 2 weeks
• Rarely need additional treatment
• Severe reactions (vasculitis-type) may need short-term low-dose steroids

Financial Constraints

Supportive Conversation:

• Acknowledge financial reality
• Discuss treatment duration and total costs transparently
• Consider shorter proven protocols (42 days for effusive cases)
• Explain monitoring requirements and costs
• Discuss euthanasia as humane option if treatment not feasible

Ethical Framework:

• Patient welfare is paramount
• Quality of life assessment ongoing
• Euthanasia preferable to untreated suffering
• Support client decision-making without judgment

Client Communication Guidance

Explaining FIP Diagnosis

Key Points to Cover:

• FIP is caused by mutation of common feline coronavirus
• Mutation occurs within individual cat (not typically transmitted cat-to-cat in mutated form)
• Historically always fatal, now treatable with antivirals
• Diagnosis based on preponderance of evidence, not single test
• FCoV antibodies in many healthy cats (not diagnostic of FIP)

Avoid:

• Guaranteeing 100% diagnosis without histopathology
• Blaming owner for cat's FIP (stress factors are just associations, not causes)
• False hope or false doom
• Jargon without explanation

Discussing Treatment Options

Present Honestly:

• Treatment availability varies by region
• GS-441524 not licensed for veterinary use in many areas
• Clients may obtain from unregulated sources
• Variable drug quality possible
• Treatment is expensive (typically thousands of dollars)
• Duration is lengthy (12+ weeks minimum)

Emphasize:

• 85% cure rate with proper protocol

• Importance of veterinary monitoring
• Commitment required (daily injections, regular monitoring)
• You will support monitoring regardless of drug source

Prognostic Factors:

• Young cats: Better outcomes
• Wet FIP: Easier to treat than dry
• No neurological involvement: Better prognosis
• Early treatment: Better outcomes

Setting Expectations

Realistic Timeline:

• Rapid initial response (24-72 hours) expected
• Near-normal by 2-4 weeks in most cases
• Full treatment 12+ weeks
• 12-week observation period after treatment
• Total commitment: 6+ months

Financial Reality:

• Estimate total costs including drug, monitoring, supportive care
• Discuss payment plans if available
• Acknowledge this is major financial commitment

Possible Outcomes:

• Cure (>85%)
• Relapse requiring additional treatment
• Drug resistance (partial or complete)
• Treatment failure
• Financial limitation requiring euthanasia

Supporting Difficult Decisions

When Treatment Not Pursued:

• Validate client's decision
• Emphasize quality of life
• Discuss euthanasia as compassionate option
• Provide grief support resources

When Treatment Fails:

• Explain not a failure of client commitment
• Some cats develop resistance
• Euthanasia discussion when appropriate
• Support through grief

Special Scenarios

Multi-cat Households

Risk Assessment:

• Other cats likely already exposed to FCoV
• Mutation theory: Each FIP case requires new mutation
• Direct transmission of mutated form unlikely in natural settings

Management Recommendations:

• No need to isolate FIP cat from established household
• Reduce stress for all cats
• Monitor other cats for clinical signs
• Consider testing siblings if feasible
• Excellent litter box hygiene

Cattery Considerations:

• Pause breeding during FIP case
• Siblings at higher risk
• Avoid stress (overcrowding, excessive showing, frequent sales)
• Do NOT use antivirals as "preventive" (resistance risk)

Preventive Measures

Reduce FIP Risk:

• Small stable groups (≤3 cats ideal)
• Reduce stress in multi-cat households
• Excellent litter box hygiene
• Avoid overcrowding

FIP Vaccine:

• Available in some countries (Felocell FIP)
• Given intranasally at ≥16 weeks
• Efficacy controversial
• Not recommended by ABCD
• Most cats already exposed before vaccine age

Testing for FCoV:

• Fecal PCR can identify shedders
• Allows separation in catteries if feasible
• Requires multiple samples (intermittent shedding)
• Most practical in breeding operations

Key Principles Summary

1. Diagnosis requires preponderance of evidence - Multiple findings, not single test

2. Follow diagnostic trees systematically - Don't skip steps or premature closure

3. Rule out treatable alternatives - Many differentials are curable

4. Confirm diagnosis before treatment when possible - Collect samples early

5. Treatment requires commitment - 12+ weeks, daily injections, regular monitoring

6. Monitor objectively - Weight, temperature, blood values, not just subjective assessment

7. Adjust treatment based on response - Increase dose if inadequate response

8. Overall clinical picture matters most - Not single test value in isolation

9. Young cats with wet FIP have best prognosis - Neurological worst prognosis

10. Support clients through entire journey - Regardless of drug source or ultimate outcome

References and Resources

Detailed Information

For comprehensive details on specific topics:

• Diagnostic Flowcharts: diagnostic-flowcharts.md

  • Evidence weighting system
  • Four diagnostic trees (A, B, C, D)
  • Confirmatory testing interpretation
  • Treatment trial considerations

• Treatment Protocols: treatment-protocols.md

  • Detailed dosing by disease form
  • Monitoring protocols and parameters
  • Dosage adjustment guidelines
  • Relapse management
  • Drug resistance handling
  • Injection site management
  • Supportive care recommendations

• Differential Diagnoses: differential-diagnosis.md

  • Effusive diseases
  • Neurological diseases
  • Ocular diseases
  • Infectious diseases
  • Neoplastic conditions
  • Metabolic/toxic conditions
  • Diagnostic approach algorithms

• Prevention and Management: prevention-management.md

  • Environmental management strategies
  • Multi-cat household guidance
  • Cattery breeding considerations
  • Shelter management protocols
  • FCoV testing interpretation
  • Vaccination discussion
  • Risk reduction strategies

Evidence Base

This skill is based on:

• ABCD (European Advisory Board on Cat Diseases) Guidelines, November 2024
• UC Davis Veterinary School research (Dr. Niels C. Pedersen group)
• Published field trials of GS-441524
• Peer-reviewed veterinary literature

Limitations

What This Skill Cannot Do:

• Replace histopathology for definitive diagnosis
• Guarantee treatment success (resistance, misdiagnosis possible)
• Provide legal advice on drug procurement
• Replace clinical judgment in complex cases

When to Seek Additional Expertise:

• Complex neurological cases requiring advanced imaging
• Ophthalmological procedures (aqueous humour sampling)
• Surgical interventions needed
• Treatment-refractory cases
• Concurrent complex diseases

Quick Decision Trees

Is This FIP?

1. High suspicion signalment? (young, multi-cat, stressed) → Yes: Continue assessment → No: Consider alternative diagnoses more

2. Compatible clinical signs? (fever, effusion, neurological, ocular) → Yes: Continue workup → No: Reconsider diagnosis

3. Laboratory findings supportive? (high globulin, low A:G, appropriate effusion) → Yes: Proceed to confirmatory testing → No: Reconsider or investigate further

4. Confirmatory testing? (positive immunostaining or high PCR loads with appropriate sample) → Yes: FIP very likely, consider treatment → No: FIP less likely, consider alternatives or continue monitoring

5. Alternative diagnoses ruled out? (See differential-diagnosis.md) → Yes: Proceed with FIP management → No: Investigate alternatives

Should Treatment Be Started?

1. Is diagnosis FIP very likely or confirmed? → No: Complete diagnostic workup first → Yes: Continue assessment

2. Owner commitment available? (financial, time, emotional) → No: Discuss alternatives including euthanasia → Yes: Continue planning

3. Baseline tests obtained? → No: Obtain CBC, chemistry, weight, photos → Yes: Continue planning

4. Appropriate starting dose determined? (based on disease form) → No: Review treatment-protocols.md → Yes: Initiate treatment

5. Monitoring plan established? → No: Set up schedule for owner tracking and vet checks → Yes: Begin treatment

Is Treatment Working?

1. Early response (24-72 hours)? (temperature, appetite, activity) → No: Consider dosage increase or reconsider diagnosis → Yes: Continue treatment

2. Short-term response (2-4 weeks)? (clinical signs, weight) → No: Increase dosage → Yes: Continue current dose

3. Mid-term blood values (4-8 weeks)? (improving toward normal) → No: Increase dosage and investigate → Yes: Continue treatment

4. All parameters normal at 12 weeks? → No: Extend treatment or increase dose → Yes: Stop treatment, monitor for relapse

Troubleshooting Common Issues

"Clinical signs not improving despite treatment"

Assess:

• Verify drug quality and source
• Check dosage calculation (mg/kg correct?)
• Evaluate injection technique
• Review diagnosis (is it actually FIP?)
• Check for concurrent disease
• Consider partial drug resistance

Action:

• Increase dosage by 2-5 mg/kg
• Recheck blood work
• Consider imaging for complications
• Reassess diagnosis if no response to increase

"Blood values not normalizing"

Assess:

• Which specific values abnormal?
• Overall clinical picture (is cat healthy appearing?)
• Magnitude of abnormality (slightly off vs markedly abnormal)
• Trend over time (improving vs static vs worsening)

Action:

• If single marginally abnormal value + healthy cat → Consider stopping at 12 weeks
• If multiple abnormal values → Extend treatment
• If markedly abnormal → Increase dosage

"Owner reports injection site problems"

Assess:

• Site rotation adequate?
• Injection depth correct?
• Severity of reaction
• Pattern (every injection vs specific sites)

Action:

• Review injection technique with owner
• Recommend gabapentin pre-treatment
• Dilute hydrogen peroxide cleaning protocol
• Consider switching to oral if dosage allows (<10 mg/kg equivalent)

"Suspected relapse after treatment"

Assess:

• Clinical signs (fever, weight loss, decreased activity?)
• Blood work (rising globulin, falling A:G?)
• Form of relapse (CNS, ocular, systemic?)
• Time since stopping treatment

Action:

• Confirm relapse with blood work
• Restart treatment at higher dose (previous + 5 mg/kg minimum)
• Plan minimum 8-week retreatment
• Use injectable form
• Consider inadequate initial treatment or resistance developing

"Client wants to stop treatment early"

Assess:

• Reason for wanting to stop (financial, improved cat, injection difficulty?)
• Current duration of treatment
• Clinical response so far
• Risk of relapse

Discussion:

• Explain relapse risk if stopped prematurely
• Consider shorter proven protocols if appropriate (42 days for effusive)
• If financial: Discuss options, payment plans
• If cat looks healthy: Review objective measures
• Support decision while providing education

Action:

• If <8 weeks: Strongly discourage unless cat unhealthy
• If 8-12 weeks with complete response: May consider in selected cases
• If ≥12 weeks: Assess stopping criteria
• Document discussion and decision

Remember

• FIP is no longer an automatic death sentence
• Support and guide clients through difficult journey
• Use objective measures for decision-making
• Be honest about prognosis, costs, and commitment
• Each case is individual - guidelines inform, not dictate
• Preserve quality of life as paramount goal
• You are the cat's advocate and the client's support

When in doubt, consult the detailed reference documents or relevant literature.